Back to top
more

Intellia Therapeutics (NTLA)

(Delayed Data from NSDQ)

$24.84 USD

24.84
833,330

-0.04 (-0.16%)

Updated May 24, 2024 03:59 PM ET

After-Market: $24.85 +0.01 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for NTLA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Intellia Therapeutics, Inc. [NTLA]

Reports for Purchase

Showing records 221 - 240 ( 278 total )

Company: Intellia Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 221

02/10/2020

Company Report

Pages: 6

In Vivo and Ex Vivo Therapies Show Encouraging Preclinical Data

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 25.00

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 222

01/10/2020

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 223

01/09/2020

Company Report

Pages: 6

ATTR and AML Plans Are On Track With Cash Runway Through 2021

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 25.00

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 224

12/17/2019

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 225

12/16/2019

Company Report

Pages: 5

Intellia Is Now Entitled to the Majority Share of Worldwide ATTR Sales

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 10.00

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 226

12/12/2019

Industry Report

Pages: 47

ASH 2019: Hangover: Covered Companies Roundup

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 100.00

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 227

11/01/2019

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 228

10/31/2019

Company Report

Pages: 8

Naming Next Dev Candidate by YE, Lead Program in Clinic Mid-2020

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 229

10/31/2019

Company Report

Pages: 6

3Q19: Modular Therapy May Unlock Opportunities. ''2001 IND Filing On Track

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 25.00

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 230

10/25/2019

Daily Note

Pages: 17

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 50.00

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 231

10/25/2019

Daily Note

Pages: 6

Preclinical Programs Push Ahead

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 232

10/18/2019

Industry Report

Pages: 10

HEALTHCARE - The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 233

08/02/2019

Daily Note

Pages: 17

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 50.00

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 234

08/02/2019

Company Report

Pages: 7

2Q Financials; NTLA-2001 IND Filing Guided for Mid-2020

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 235

08/01/2019

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 236

08/01/2019

Company Report

Pages: 5

2Q19 Update - Progress Is Being Made, NTLA-2001 IND Filing In Mid-2020

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 10.00

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 237

06/10/2019

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 238

06/09/2019

Company Report

Pages: 25

Fully Valued Ahead of FIH Studies. Initiating at Neutral. $16 PT.

Provider: Roth Capital Partners, Inc.

Price: 75.00

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 239

05/03/2019

Daily Note

Pages: 15

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Price: 50.00

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 240

05/03/2019

Company Report

Pages: 9

UPGRADING to OP; ATTR IND in 2020; Cell Therapy Program at the Heels

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party